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Abstract
Background: Praziquantel (PZQ) is an isoquinoline derivative (2-cyclohexylcarbonyl-1, 2, 3, 6, 7, 11b-hexahydro-4H-
pyrazino{2,1-a}-isoquinoline-4-one), and is currently the drug of choice for all forms of schistosomiasis. Silymarin, a
standardized milk thistle extract, of which silibinin is the main component, is known for its hepatoprotective, anti-
inflammatory, antioxidant activities, and hepatocyte regeneration. This study investigates the anti-inflammatory/anti-
fibrotic effects of silymarin and/or PZQ on schistosomal hepatic fibrosis.
Methods: Schistosoma mansoni-infected mice were divided into two large groups (I & II), each with four
subgroups and were run in parallel. (i) Infected untreated; (ii) treated with silymarin, starting from the 4th (3 weeks
before PZQ therapy) or 12th (5 weeks after PZQ therapy) weeks post infection (PI); (iii) treated with PZQ in the 7th
week PI; and (iv) treated with silymarin, as group (ii) plus PZQ as group (iii). Comparable groups of uninfected mice
run in parallel with the infected groups. Mice of groups I and II were killed 10 and 18 weeks PI, respectively.
Hepatic content of hydroxyproline (HYP), serum levels and tissue expression of matrix metalloproteinase-2 (MMP-2),
transforming growth factor-b1 (TGF-b1) and number of mast cells were determined. In addition, parasitological,
biochemical and histological parameters that reflect disease severity and morbidity were examined.
Results: Silymarin caused a partial decrease in worm burden; hepatic tissue egg load, with an increase in
percentage of dead eggs; modulation of granuloma size, with significant reduction of hepatic HYP content; tissue
expression of MMP-2, TGF-b1; number of mast cells, with conservation of hepatic reduced glutathione (GSH). PZQ
produced complete eradication of worms, eggs and alleviated liver inflammation and fibrosis. The best results were
obtained, in most parameters studied, in groups of mice treated with silymarin in addition to PZQ.
Conclusions: Our results point to silymarin as a promising anti-inflammatory and anti-fibrotic agent; it could be
introduced as a therapeutic tool with PZQ in the treatment of schistosomal liver fibrosis, but further studies on
mechanisms of silymarin and PZQ in chronic liver diseases may shed light on developing therapeutic methods in
clinical practice.
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Background
Schistosomiasis caused by S. mansoni continues to be an
important cause of parasitic morbidity and mortality
worldwide and is the most common fibrotic disease to
arise due to inflammation and the deposition of scar tis-
sue around parasite eggs trapped in the liver [1]. It is
usually characterized by an unnoticed acute phase, fol-
lowed by liver fibrosis at chronic and advanced stages
[2]. In fibrosis, an excessive deposition of extracellular
matrix (ECM) components is observed, such as type III
collagen in the fibrotic process, and types I and II col-
lagen, fibronectin and proteoglycan at various stages of
granuloma formation [3]. The activated hepatic stellate
cells (HSCs) have now been identified as the primary
source of extracellular matrix synthesis in liver fibrogen-
esis [4]. Fibrogenic cytokines, like transforming growth
factor-b (TGF-b) are among the major cytokines
involved in the activation process, causing enhanced
proliferation of HSCs and matrix synthesis [5]. Mast cell
hyperplasia in the liver has also been observed in a vari-
ety of experimental models of rat-liver fibrosis, such as
that induced by CCl4, diethylnitrosamine, radiation, por-
cine serum, and bile duct resection [6]. Mast cells,
which are derived from hematopoietic progenitors, leave
the bone marrow and migrate to areas of inflammation.
TGF-b1 is the most potent mast cell chemo-attractant
and is responsible for this directional migration at fem-
tomolar (fM) concentrations, and tissue maturation of
mast cells [7]. Thus, the activation of mast cells and the
subsequent exocytosis of granules are followed by pro-
duction and secretion of cytokines and other factors
that lead to leukocyte infiltration and local inflammation
[8]. Matrix metalloproteinases (MMPs) are the major
enzymes that degrade the various types of collagen. In
the liver, MMP-2 is produced abundantly by the acti-
vated HSCs and fibroblasts, although other resident liver
cells may be minor producers of MMP-2
[9]. It is well known that fibrosis is reversible whereas
cirrhosis is irreversible, so it is important to prevent
fibrosis progressing to cirrhosis. However, there is no
ideal anti-fibrotic drug to date. Available therapies for
many chronic liver diseases are ineffective, with liver
transplantation as the only option. Novel approaches
that attack the scarring response are therefore urgently
needed [10]. Praziquantel (PZQ), as a safe anti-schisto-
some drug, has been used for more than 30 years [11].
In general, specific treatment of schistosomiasis results
in parasite elimination, and later on, a slight reduction
in hepatic fibrosis that is attributed to parasite eradica-
tion [12]. Silymarin, a standardized extract of the milk
thistle (Silybum marianum [L.] Gaertner) has a long tra-
dition as an herbal remedy; it was introduced as a
“hepatoprotective” agent more than 30 years ago and
used clinically in Europe and Asia for the treatment of
liver diseases [13,14]. Silymarin consists of four flavono-
lignan isomers namely: silybin (also known as silybinin
or silibinin), isosilybin, silydianin and silychristin [13].
Silybin is the most prevalent and biologically active of
the four isomers and represents about 60-70% of sily-
marin, followed by silychristin (20%), silidianin (10%),
and isosilybin (5%). Silymarin offers good protection in
various toxic models of experimental liver diseases in
laboratory animals. The protective action of silymarin is
explicable in terms of its capacity for trapping free radi-
cals and has a stabilizing effect on the cytoplasmic
membranes. It promotes protein synthesis, helps in
regenerating liver tissue, enhances glucuronidation and
protects against glutathione depletion. Moreover, it is a
potent anti-inflammatory, immunomodulatory and anti-
fibrogenic agent in the liver [8,15]. In a recent study by
Mata-Santos, et al. [16] on the effect of silymarin treat-
ment in experimental schistosomiasis, silymarin did not
affect parasite oviposition capacity; reduced granuloma-
tous peri-ovular reaction in the liver, and decreased
hepatic fibrosis in this infection. Since research into the
effect of silymarin on schistosomal hepatic fibrosis is
very limited, we are interested to test its anti-inflamma-
tory/anti-fibrotic effects alone and with the anti-schisto-
somal PZQ, on acute and chronic schistosomal liver
fibrosis. Parasitological criteria, function and histo-
pathology of the liver, serum and tissue markers of liver
fibrosis were also examined.
Methods
Drugs and dosage
Silymarin (Legalon®) purchased from (Chemical Indus-
tries Development (CID), Giza, Egypt under License of:
Madaus GmbH. Germany) was given orally in a dose of
750 mg/kg/day [17], 5 days/week for 6 weeks in the
form of aqueous suspension in 2% Cremophor El
(Sigma Chemical Co., St. Louis, MO, USA). Praziquan-
tel® (Praziquantel-Sedico Pharmaceutical Co. 6th of
October City, Egypt) was given orally in a total dose of
1000 mg/kg divided equally on two consecutive days
[18] in the form of aqueous suspension in 2% Cremo-
phor El.
Animals
Eighty CD-1 Swiss male albino mice, weighing 18-20 g
were provided by the Schistosome Biology Supply Cen-
ter (SBSC) of the Theodor Bilharz Research Institute
(TBRI), Giza, Egypt. The mice were maintained on a
standard commercial pelleted diet (El-Kahira company
for oils and soap) in an air-conditioned animal house at
20-22°C. The animal experiments were conducted at the
TBRI animal unit in accordance with international,
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ethical guidelines after approval of the institutional ethi-
cal committee of TBRI.
Infection of animals
Animals were infected with the Egyptian strain of S.
mansoni (70 ± 5 cercariae/mouse) using the body
immersion technique according to the method described
by Liang et al. [19].
Experimental design
Experiment I (acute infection): S. mansoni-infected mice
were divided into 4 groups, Group (i) infected mice
received the vehicle (2% Cremophor El), Group (ii) trea-
ted with silymarin starting from the 4th week (3 weeks
before PZQ therapy) to the 10th week PI. Group (iii)
treated with PZQ in the 7th week PI and Group (iv)
treated with both silymarin and PZQ at the same time
intervals as described in Groups (ii) and (iii).
Experiment II (chronic infection): S. mansoni-infected
mice were divided into 4 groups, Group (i) infected
mice received the vehicle (2% Cremophor El), Group
(ii) treated with silymarin starting from the 12th week (5
weeks after PZQ therapy) to the 18th week PI. Group
(iii) treated with PZQ in the 7th week PI and Group
(iv) treated with both silymarin and PZQ at the same
time intervals as described in Groups (ii) and (iii). Ani-
mals of experiments I and II were killed by decapitation
10 and 18 weeks PI, respectively. Comparable groups of
uninfected mice received the vehicle (2% Cremophor El)
and were run in parallel with the infected groups and
killed at a time corresponding to 10 and 18 weeks PI,
respectively.
After decapitation, blood was collected and sera were
separated by centrifugation at 1850 g for 10 minutes
and stored frozen at -70°C prior to the pending assay.
The livers were immediately chilled on ice and a piece
of 0.5 g was homogenized using a Potter glass homoge-
nizer equipped with a teflon pestle in 2.5 volumes (w/v)
ice cold 0.1 M potassium phosphate buffer adjusted to
pH 6.5. The crude homogenate was then centrifuged at
10.000 g for one hour at 4°C and the supernatant was
harvested and snap frozen at -80°C in Eppendorf vials
for subsequent analysis of the hepatic content of
reduced glutathione (GSH). Another gram of liver was
homogenized in 5 volumes (w/v) of 0.9% cold normal
saline (0.9% NaCl). The crude homogenate was har-
vested and stored frozen at -70°C in Eppendorf vials for
subsequent analysis of the hepatic content of HYP.
Assessment of parasitological criteria
Hepatic and portomesenteric vessels were perfused [20]
to recover worms for subsequent counting. The number
of ova per gram of liver or intestine tissues was counted
[21]. Percentage of the different egg developmental
stages (oogram pattern) was examined [22].
Histopathology and granuloma measurement
Livers recovered from mice were fixed in 10% buffered
formalin and processed to paraffin blocks. Sections (4
μm thick) were cut 250 μm away from the preceding
sections to avoid measurement of the same granuloma.
Five paraffin liver sections were prepared from each ani-
mal and stained with haematoxylin and eosin (H&E)
and Masson trichrome stains. Measurements of the
granuloma size were conducted on non-contiguous
granulomas, each containing a single egg (with intact or
degenerated miracidia), using an ocular micrometer.
The mean diameter of each granuloma was calculated
by measuring two diameters of the lesion at right angles
to each other [23]. For each mouse, 40 granulomas were
measured and associated hepatic histopathological
changes were studied.
Liver function tests
Concentrations of alanine aminotransferase (ALT) and
albumin in the collected sera were estimated using the
available commercial kits (Sentinel CH, Milan, Italy).
The level of reduced glutathione was determined in liver
homogenate according to the method described by Ell-
man [24]. Briefly, 0.5 ml homogenate was added to a
tube with 0.5 ml of 10% trichloroacetic acid. The tubes
were centrifugated at 3000 g for 10 min. A 0.2 ml ali-
quot of the resulting supernatant was added to a tube
containing 5 ml of 0.1 M phosphate buffer and 0.1 ml
of 5, 5’-dithio-bis-(2-nitro benzoic acid; DTNB) solution
(Ellman’s reagent) and the absorbance was measured at
412 nm. A standard graph was drawn using different
concentrations of a standard GSH solution (1 mg/ml).
With the help of the standard graph, the GSH contents
in the liver homogenates of the experimental animals
were calculated.
Liver fibrosis markers
As an index of liver fibrosis, (a) hydroxyproline was esti-
mated in the liver using the method of Woessner [25].
Briefly, 0.5 ml of 20% liver homogenate was digested in
1 ml of 6 mol/L HCl at 120°C for 8 hours. An aliquot of
digested homogenate (25 ml) was added to 25 ml
citrate-acetate buffer and finally 500 ml of chloramines-
T-solution was added and the mixture was left at room
temperature for 20 min. Then, 500 ml Ehrlich’s solution
was added and the mixture was incubated at 65°C for 15
minutes. After cooling for 10 minutes, the color that
developed was measured spectrophotometrically at 550
nm. (b) serum matrix metalloproteinases type-2 (MMP-
2) determined using an ELISA kit (Quantikine R&D
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Systems, Minneapolis, Minnesota, USA) and (c) serum
transforming growth factor b1 (TGF-b1) was deter-
mined using an ELISA kit (IBL International, GmbH,
Hamburg, Germany).
Immunohistochemical procedure
The standard avidin-biotin immunoperoxidase technique
was used [26]. Paraffin sections (5 μm thick) were cut
on positively charged slides, dewaxed in xylene and
hydrated in descending grades of ethanol. The endogen-
ous peroxidase activity was quenched by incubation in
100% methanol with 3% hydrogen peroxide for 20 min-
utes. Antigen retrieval was performed by subjecting the
sections, in citrate buffer (pH 7.0), to 15 minutes of
microwaves at 700 W. Sections were incubated over-
night at +4°C in a humid chamber with primary anti-
mouse monoclonal antibodies against TGF-b1 and
MMP-2 (Santa Cruz Biotechnology, California, USA).
The antibodies were diluted 1:50 and 1:100 respectively,
in phosphate buffer saline (PBS). After rinsing in PBS,
the sections were incubated at room temperature for 15
minutes with biotinylated secondary anti-mouse anti-
body and after a further wash in PBS, the slides were
incubated with an avidin-biotin complex horseradish
peroxidase solution (DAKO, Glostrup, Denmark). After
10 minutes of incubation, the peroxidase reaction was
developed using 0.01% hydrogen peroxide in 0.05% dia-
minobenzidine tetrahydrochloride (DAB). Sections were
counterstained with Meyer’s hematoxylin and dehy-
drated in ethanol prior to mounting. Liver sections with
the primary antibody replaced with PBS, served as nega-
tive controls, while colonic cancer sections served as
TGF-b1 and MMP-2-positive controls.
The liver sections were examined using a Zeiss light
microscope (Oberkochen, Germany). The number of
positively stained cells with the highest expression
recorded within 10 successive fields (x400) was counted
per section animal in a semi-quantitative way for both
markers; the final value represented the mean of 80
readings per group. Zero percentage was given to
unstained sections. TGF-b1 expression sites were exam-
ined intralobularly, in the periportal areas, in hepato-
cytes, and granuloma [27]. MMP-2 expression sites were
examined in hepatocytes, Kupffer cells and endothelial
cells lining sinusoids and granuloma [28].
Number of mast cells in liver tissue
Toluidine blue staining for mast cells was performed by
immersion of liver sections in 0.1% toluidine blue
(Sigma, USA) for 3-5 minutes at room temperature [29].
Both intact and degranulated mast cells as well as the
total number of mast cells was quantified in 10 succes-
sive selected, non-overlapping, high power fields (x400)
of each liver section [30].
Statistical analysis
Data was analysed using version 11.0 of the SPSS soft-
ware package (SPSS Inc., Chicago, IL, USA), with the
results expressed as means with standard errors. Group
means were compared using unpaired Student’s t-tests.




Treatment of infected mice with silymarin for 6 weeks
starting from the 4th and 12th weeks PI resulted in a reduc-
tion in the total worm burden; recovered 10 and 18 weeks
PI by 26.25% (P > 0.05) and 39.39% (P < 0.001) respec-
tively when compared to the infected untreated group.
Moreover, a significant reduction (P < 0.01) in the hepatic
tissue egg load by 28.73% and 43.13%, accompanied with
significant increase (P < 0.05, P < 0.01) in the percentage
of dead eggs was observed 10 and 18 weeks PI, respec-
tively. Administration of PZQ alone or with silymarin
resulted in 97-100% worm and egg eradication with ~77%
reduction in the hepatic tissue egg load with no significant
difference recorded between the two groups (Table 1).
Histopathological changes
Ten weeks post infection; the inflammatory granulomatous
lesions were mainly seen in the hepatic parenchyma and to
a lesser extent in the portal tracts. Fibrocellular granulo-
mas, constituted around 60% of the estimated granulomas
with mean granuloma diameter 403.83 ± 15.76 μm. In the
chronic stage of S. mansoni infection (18 weeks PI) with
immune modulation, fibrocellular granulomas (around
80% of the estimated granuloma) had fewer inflammatory
cells and more fibrous tissue content with mean diameter
of 349.50 ± 4.50 μm. With the progression of infection, the
portal tracts were more expanded by the amalgamated
granulomatous lesions that had developed around the
newly deposited ova with subsequent collagen deposition
along portal tracts. Treatment with PZQ reduced both the
granuloma size and inflammatory cells 10 and 18 weeks PI.
In addition, administration of silymarin to infected mice
resulted in the regression of the granulomatous inflamma-
tory reaction with significant reduction in granuloma size,
10 and 18 weeks PI when compared with their correspond-
ing infected untreated groups. Administration of PZQ with
silymarin resulted in a marked decrease in inflammatory
cells in portal tracts and granulomas, with significant
reduction in granuloma size (P < 0.05, P < 0.001), 10 and
18 weeks PI respectively, when compared to their corre-
sponding PZQ treated groups (Figure 1).
Liver function assessments
Infection of mice with S. mansoni showed a significant
increase in serum levels of ALT (P < 0.01, P < 0.001)
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with a significant decrease in both albumin (P < 0.01) 18
weeks PI, and hepatic GSH (P < 0.001) 10 and 18 weeks
PI in comparison with the uninfected untreated group.
Compared to the infected untreated group, ALT level
was significantly decreased in the group treated with
either PZQ (P < 0.05, P < 0.01)) or silymarin (P < 0.05;
18 weeks PI) alone or with both drugs (P < 0.01, P <
0.001) 10 and 18 weeks PI, respectively. Moreover,
serum albumin was significantly elevated in groups trea-
ted with either PZQ alone (P < 0.01) or combined with
silymarin (P < 0.05) 18 weeks PI. In addition to that, the
hepatic GSH was significantly elevated in groups treated
with PZQ alone (P < 0.05, P < 0.001), silymarin alone (P
< 0.01) or both (P < 0.01, P < 0.001), 10 and 18 weeks
Table 1 Effect of silymarin with/without praziquantel on total worms, hepatic tissue egg load and % dead eggs 10
and 18 weeks post infection of mice with S.mansoni
Animal groups Total worms Hepatic tissue egg load × 103 % dead eggs
10 wks 18 wks 10 wks 18 wks 10 wks 18 wks
Infected (Vehicle) 19.16 ± 2.18 20.28 ± 0.99 16.22 ± 1.40 27.08 ± 3.53 7.16 ± 0.94 6.87 ± 0.99















































Data are presented as mean ± SEM (n = 8 in each group).
Mice were administered praziquantel (PZQ; 500 mg/kg/day for 2 days) in the 7th week post infection (PI) and silymarin (750 mg/kg/day, 5 days/week for 6 weeks)
at the 4th and 12th weeks PI for 6 weeks and were killed 10 and 18 weeks PI respectively. Numbers in parentheses indicate the percentage of reduction from
infected (vehicle) group.




























10 weeks 18 weeks
Figure 1 Effect of silymarin with/without praziquantel on hepatic granuloma size, 10 and 18 weeks post-infection of mice with S.
mansoni. *** significantly different from infected (vehicle) group at P < 0.001. $ significantly different from infected-PZQ treated group at P <
0.05, $$$ at P < 0.001.
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PI, respectively. Compared to the PZQ treated group,
hepatic GSH was significantly restored in the group
treated with both PZQ and silymarin 10 (P < 0.01) and
18 (P < 0.05) weeks PI (Table 2).
Liver fibrosis markers
Infection of mice with S. mansoni caused pronounced ele-
vations in both serum TGF-b1 (P < 0.001) and MMP-2 (P
< 0.01, P < 0.001) levels, 10 and 18 weeks PI respectively,
when compared to their corresponding uninfected
untreated groups. Compared to the infected untreated
group, treatment with PZQ caused a significant reduction
in both serum TGF-b1 (P < 0.001) and MMP-2 (P < 0.05,
P < 0.001) levels by (43.34%, 51.75%) and (20.73%,
39.35%), 10 and 18 weeks PI, respectively. Treatment with
silymarin resulted in a significant reduction of TGF-b1 (P
< 0.05) by 32.73% 10 weeks PI with insignificant reduc-
tions (P > 0.05) in serum TGF-b1, 18 weeks PI and MMP-
2 levels 10 and18 weeks PI. Administration of PZQ in
combination with silymarin caused normalization with sig-
nificant reduction of serum TGF-b1 (P < 0.01), 10 weeks
PI and MMP-2 (P < 0.05), 10 and 18 weeks PI, when com-
pared to the corresponding PZQ treated group (Table 3).
Infection of mice with S. mansoni induced a signifi-
cant increase (P < 0.001) in the hepatic content of HYP
10 and 18 weeks PI respectively, when compared to
their corresponding uninfected untreated groups. Treat-
ment with PZQ resulted in a significant reduction (P <
0.001) in HYP content by 34.25% and 39.61%, 10 and 18
weeks PI respectively, when compared to their corre-
sponding infected untreated groups. In addition, treat-
ment with silymarin showed significant reduction (P <
0.05) by 19.06% and 17.02% 10 and 18 weeks PI, respec-
tively. Administration of PZQ with silymarin produced
insignificant reduction in HYP content 10 and 18 weeks
PI, when compared to their corresponding PZQ treated
groups (Table 4).
Immunohistochemical aspects
The control, normal, uninfected mice were negative for
TGF-b1 and MMP-2 monoclonal antibodies. S. mansoni
infected untreated mice showed positively TGF-b1 and
MMP-2 stained hepatocytes (cytoplasmic), fibroblast
and inflammatory cells of granulomas (Figures 2 &3a,
b). Treatment with PZQ in the 7th week PI significantly
reduced the expression of TGF-b1 (Figure 2a & b) and
MMP-2 (Figure 3a & b) by (70.75%, 52.88%; P < 0.001)
and (29.72%; P < 0.05, 64.66%; P < 0.001) respectively,
when compared with their corresponding infected
untreated groups, 10 and 18 weeks PI respectively
(Table 4). Treatment with silymarin in the 4th and 12th
weeks PI significantly reduced (P < 0.001) the expression
of TGF-b1 (Figure 2a & b) and MMP-2 (Figure 3a & b)
by 49.60%, 48.61% and 47.30%, 29.00%, respectively,
when compared with their corresponding infected
untreated groups, 10 and 18 weeks PI, respectively. In
groups treated with both PZQ and silymarin, the reduc-
tion in the expression of TGF-b1 (Figure 2a & b) was
significant and reached 84.13% and 67.09% (P < 0.01)
versus PZQ alone (70.75%, 52.88%) 10 and 18 weeks PI,
respectively. Meanwhile, the reduction in the expression
of MMP-2 (Figure 3a & b) was 44.59% (P < 0.05) and
70.80% (P > 0.05) versus PZQ alone (29.72%, 64.66%) 10
and 18 weeks PI, respectively (Table 4).
Recruitment of mast cells in liver tissue
In toluidine blue-stained liver sections from the S.man-
soni-infected group, mast cells were oval in shape with
Table 2 Effect of silymarin with/without praziquantel on liver function tests, 10 and 18 weeks post-infection of mice
with S.mansoni






10 wks 18 wks 10 wks 18 wks 10 wks 18 wks









































Data are presented as mean ± SEM (n = 8 in each group).
Mice were administered praziquantel (PZQ; 500 mg/kg/day for 2 days) in the 7th week post infection (PI) and silymarin (750 mg/kg/day, 5 days/week for 6 weeks)
at the 4th and 12th weeks PI for 6 weeks and were killed 10 and 18 weeks PI respectively.
ALT, Alanine aminotransferase; GSH, reduced glutathione.
† Significantly different from uninfected (vehicle) group at P < 0.05, †† at P < 0.01 and ††† at P < 0.001. ‡ Significantly different from infected (vehicle) group at
P < 0.05, ‡‡ at P < 0.01 and ‡‡‡ at P < 0.001. § Significantly different from infected treated with PZQ group at P < 0.05 and §§ at P < 0.01.
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metachromatic granules in portal areas and in the gran-
uloma. At 10 and 18 weeks PI, the number of mast cells
was 5.00 ± 0.36 and 3.83 ± 0.48/10 successive fields,
respectively (Figure 4). However, in the infected PZQ-
treated group, the number of mast cells was significantly
decreased (P < 0.001) by 66.60% and 60.84%, 10 and 18
weeks PI respectively, compared with the infected
untreated group. Also, in the infected silymarin-treated
group, the number of mast cells was decreased
significantly (P < 0.001) by 83.40% and 91.38% 10 and
18 weeks PI, respectively. Meanwhile, in the infected
group treated with both PZQ and silymarin, complete
absence of mast cells was observed 10 and 18 weeks PI,
respectively (Figure 5a, b).
Discussion
Although chemotherapy eliminates matured worms
effectively and prevents the accumulation of schistosome
Table 3 Effect of silymarin with/without praziquantel on serum transforming growth factor-b1 and matrix
metalloproteinase-2, 10 and 18 weeks post infection of mice with S.mansoni
Animal groups Serum TGF-b1 (ng/ml) Serum MMP-2 (ng/ml)
10 wks 18 wks 10 wks 18 wks













































Data are presented as mean ± SEM (n = 8 in each group).
Mice were administered praziquantel (PZQ; 500 mg/kg/day for 2 days) in the 7th week post infection (PI) and silymarin (750 mg/kg/day, 5 days/week for 6 weeks)
at the 4th and 12th weeks PI for 6 weeks and were killed 10 and 18 weeks PI respectively. Numbers in parentheses indicate the percentage of reduction from
infected (vehicle) group.
†† Significantly different from uninfected (vehicle) group at P < 0.01 and ††† at P < 0.001. ‡ Significantly different from infected (vehicle) group at P < 0.05, ‡‡ at
P < 0.01 and ‡‡‡ at P < 0.001. § Significantly different from infected treated with PZQ group at P < 0.05 and §§ at P < 0.01.
Table 4 Effect of silymarin with/without praziquantel on hepatic hydroxyproline content and immunohistochemical
expression of transforming growth factor-b1 and matrix metalloproteinase-2, 10 and 18 weeks post-infection of mice
with S.mansoni
Animal groups Within 10 successive microscopic fields (×400)/section/animal
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Data are presented as mean ± SEM (n = 8 in each group).
Mice were administered praziquantel (PZQ; 500 mg/kg/day for 2 days) in the 7th week post infection (PI) and silymarin (750 mg/kg/day, 5 days/week for 6 weeks)
at the 4th and 12th weeks PI for 6 weeks and were killed 10 and 18 weeks PI respectively. Numbers in parentheses indicate the percentage of reduction from
infected (vehicle) group. TGF-b1, transforming growth factor b1; MMP-2, matrix metalloproteinase-2.
† Significantly different from uninfected (vehicle) group at P < 0.05 and ††† at P < 0.001. ‡ Significantly different from infected (vehicle) group at P < 0.05 and
‡‡‡ at P < 0.001. § Significantly different from PZQ-treated group at P < 0.05 and §§ at P < 0.01.
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Figure 2 Immunostain for TGF-b1 antibody (DAB, ×200) of infected untreated liver sections of mice killed 10 (a) and 18 (b) weeks PI
showing marked positively stained hepatocytes and granuloma (fibroblast and inflammatory cells; arrows). Sections taken from livers of
mice treated with PZQ (500 mg/kg/day for 2 days) showing mild (a) and moderate (b) positively stained hepatocytes, endothelial cells lining
sinusoids and granuloma cells (arrows). Sections taken from livers of mice treated with silymarin (750 mg/kg/day, 5 days/week for 6 weeks)
showing weak (a) and moderate (b) positively stained hepatocytes, endothelial cells lining sinusoids and granuloma cells (arrows). Sections taken
from livers of mice treated with PZQ plus silymarin showing weakly and scattered positively stained hepatocytes and granuloma cells (a, b;
arrows).
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Figure 3 Immunostain for MMP-2 antibody (DAB, ×200) of infected untreated liver sections of mice killed 10 (a) and 18 (b) weeks PI
showing marked positively stained hepatocytes and granulomas (arrows). Sections taken from livers of mice treated with PZQ (500 mg/
kg/day for 2 days) showing moderate (a) and mild (b) positively stained hepatocytes, endothelial cells lining sinusoids and granuloma cells
(arrows). Sections taken from livers of mice treated with silymarin (750 mg/kg/day, 5 days/week for 6 weeks) showing mild (a) and moderate (b)
positively stained hepatocytes, endothelial cells lining sinusoids and granuloma cells (arrows). Sections taken from livers of mice treated with
PZQ plus silymarin showing scattered positively stained hepatocytes, weak positively stained endothelial cells lining sinusoids and granuloma
cells (a; arrows) and mild positively stained hepatocytes, weak positively stained endothelial cells lining sinusoids and granuloma cells (b; arrows).
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eggs, less effective drugs are directed to reversing the
existing hepatic fibrosis, especially at the chronic and
advanced stages of schistosomiasis. Therefore, treatment
targeting hepatic fibrosis of schistosomiasis remains a
challenging proposition [31]. Because the mouse model
has a similar course to human schistosomiasis [32], we,
thus, established the mouse schistosomiasis model
through Schistosoma mansoni cercariae infection, and
then treated them with either silymarin alone or plus
praziquantel to diminish liver fibrosis in the current
study. In this study, all mice received S. mansoni infec-
tion in addition to the presence of hepatic granulomas
around deposited schistosome eggs affecting hepatocel-
lular function. The observed elevation in ALT reflects
either acute active or chronic liver damage [33], and
hypoalbuminemia in chronic infection occurs simulta-
neously with the increase in collagen deposition. This
could be associated with malabsorption due to damaged
intestinal mucosa resulting from the extrusion of large
numbers of eggs, or could be due to decreased synthesis
which may result from parasitic injury to hepatic cells
[34]. In addition, a significant depletion of GSH, which
constitutes the first line of defence against free radicals
and is a critical determinant of tissue susceptibility to
oxidative damage, was observed. In the present study,
hydroxyproline was chosen because it is a sensitive
marker that increases significantly during liver fibrosis.
The increase in this amino acid reflects an increase in
the de novo synthesis of liver collagen and an increase
in the amount of hydroxyproline [35]. Here, there was a
linked increase in serum MMP-2, TGF-b1 and the HYP
content in both acute and chronic infections. This could
be due to the activated HSCs during the acute stage of
fibrosis producing more MMPs to counteract the over-
production of collagen-I, which was dominant from the
onset of the fibrotic response and peaked at the chronic
phase of infection [36]. Singh et al. [37] reported that
there was a strong rise in collagen I and III expression
in the liver seven weeks post infection indicating that
induction of collagen production was associated with
the early development of the granulomatous response.
In addition, MMP-2 and TGF-b1 levels continued to
rise reaching the highest level at the 18th week post
infection. Loebermann et al. [38] reported that the
expression of MMP-2 correlated well with the onset and
progression of fibrosis.
In the current study, treatment of S. mansoni-infected
mice with silymarin alone at the 4th and 12th weeks PI
resulted in remarkable worm and egg reduction accom-
panied with a partial increase in the percentage of dead
eggs 10 and 18 weeks PI. This was associated with heal-
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Figure 4 Effect of silymarin with/without praziquantel on the total number of mast cells/10 successive fields/section, 10 and 18 weeks
post-infection of mice with S. mansoni. Numbers in parentheses indicate the percentage of reduction from infected (vehicle) group. ***
Significantly different from infected (vehicle) group at P < 0.001. $$$, Significantly different from infected-PZQ treated group at P < 0.001.
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Figure 5 Toludine stain (×200) of infected untreated liver sections of mice killed 10 (a) and 18 (b) wks PI showing moderate number
of positively stained mast cells at granuloma sites (arrows). Sections taken from livers of mice treated with PZQ (500 mg/kg/day for 2 days)
showing mild positively stained mast cells (a, b arrows). Sections taken from livers of mice treated with silymarin (750 mg/kg/day, 5 days/week
for 6 weeks) showing few scattered mast cells (a) and scanty (b) positively stained mast cells at granuloma sites (arrows). Sections taken from
livers of mice treated with PZQ plus silymarin showing complete absence of stained mast cells at granuloma sites (a) & (b).
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histopathologically with reduction of granuloma size,
more granuloma circumscription, more ova degenera-
tion and fewer inflammatory cells. This may be attribu-
ted to the antioxidative properties of silymarin [39],
therefore, it is possible that silymarin eliminates the pro-
ducts of oxidative reactions and assists in the immune-
mediated destruction of worms and eggs. Also, treat-
ment with silymarin, whether in acute or chronic infec-
tion, significantly reduced the hepatic HYP content,
tissue expression of TGF-b1 and MMP-2 and the num-
ber of mast cells. This is consistent with previous stu-
dies, which showed that administration of silymarin
reduced the hepatic collagen content in diethylnitrosa-
mine [40] and CCl4 administered rats [41], and exerts
its anti-fibrotic properties by reducing TGF-b induced
de novo synthesis of collagen type I [42]. Fuchs et al.
[15] reported that prolonged treatment with silymarin
resulted in its accumulation in HSCs and down regu-
lated TGF-b1 expression; since this growth factor has
the ability to induce its own production, silymarin broke
the so-called fibrogenesis loop, or the self-perpetuation
of hepatic fibrosis. In this study, the number of mast
cells in portal areas and granulomas decreased signifi-
cantly in the silymarin-treated group compared to those
of the infected group. Mast cells secrete various media-
tors, which promote fibroblast growth, stimulate pro-
duction of the extracellular matrix by fibroblasts of
hepatic stellate cells, and produce components of the
extramedullary matrix themselves [43]. However, it is
unclear whether they play a central role in its develop-
ment. Thus, silymarin has been histopathologically
shown to have a significant anti-inflammatory effect on
hepatic tissue, including mast cell stabilization.
In the current study, silymarin alone significantly
reduced the elevated ALT and restored the depletion of
GSH with no alteration in serum albumin level 10 and
18 weeks PI. Silymarin restored the elevated level of
serum ALT in CCl4 intoxicated rats [44] and in diethyl-
nitrosamine administered rats [45] by preventing liver
damage through maintaining the integrity of the plasma
membrane, thereby suppressing the leakage of enzymes.
The increase in the hepatic GSH content may be attrib-
uted to the well established antioxidant actions of sily-
marin [39], which was able to dramatically reduce the
generation of intracellular ROS in response to different
pro-oxidant stimuli [42]. Furthermore, silymarin is cap-
able of protecting liver cells directly by stabilizing the
membrane permeability through inhibiting lipid peroxi-
dation and preventing liver glutathione depletion, thus
offering the synergistic benefit of sparing liver cells from
destruction [46].
Reversal of schistosome-induced pathology after treat-
ment with PZQ has been previously described [47]. In
contrast to that, our findings show that PZQ alone
seemed to be effective in reducing hepatic fibrosis as
shown by a clear reduction in the serum levels and tis-
sue expression of TGF-b1 and MMP-2, the number of
mast cells and hepatic HYP content at 10 and 18 weeks
PI. This was accompanied by a significant reduction in
ALT with significant restoration of albumin and GSH.
The main explanations for these results are presumed to
be a removal of schistosomal worms, and subsequent
reduction of egg deposition and granuloma size.
Researchers showed that patients in Ethiopia and
Uganda had improvement or resolution of schistosomal
periportal thickening/fibrosis after parasitologic cure
with PZQ [48,49]. Singh et al. [50] reported that with
elimination of eggs and subsidence of the inflammatory
response, collagen gene expression was minimal and
that collagen and MMP-2 gene expression diminished in
a linked fashion. The authors added that, the weakening
of the inflammatory signals, may lead to a decrease in
the activation of HSCs and diminished the production
of IL-13 by monocytes and macrophages, which in turn
reduced the stimulation of TGF-b1. In addition, in the
face of decreased collagen production and deposition,
expression of MMP-2 genes also decreased because the
bulk of the deposited fibrous tissue had been desorbed
and consequently the curtailed gene expression of
MMP-2 is appropriate [50]. In a recent study by Liang
et al. [51] on the anti-fibrotic effects of PZQ in mice
with both chronic and advanced schistosomiasis as well
as in CCl4 induced liver fibrosis mice, they mentioned
that the significant amelioration of hepatic fibrosis by
praziquantel treatment validates it as a promising anti-
fibrosis drug and offers the potential for new che-
motherapy for hepatic fibrosis resulting from
schistosomiasis.
Administration of silymarin in addition to PZQ also
showed complete eradication of worms, no viable eggs
with reduction in the hepatic tissue egg load and more
healing of hepatic granulomatous lesions revealing that
the use of silymarin along with PZQ did not interfere
with, or affect, the antischistosomal activity of PZQ. The
highest reduction observed in TGF-b1, MMP-2 and
mast cells was in the group treated with PZQ plus sily-
marin. In addition, the improvement of liver function
and histopathology whether in acute or chronic infec-
tions may be due to blocking liver fibrosis through kill-
ing parasites and complete eradication of eggs and their
toxins by PZQ to alleviate liver inflammation, and to
the anti-inflammatory, anti-fibrotic actions, in addition
to the antioxidative properties of silymarin. Although
the hepatoprotective properties of silymarin have been
reported from both in vitro and in vivo studies, its
mechanism of action still has not been established [52].
Velebný et al. [53] showed that combined treatment
with PZQ and silymarin in mice infected with
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Mesocestoides vogae (Cestoda) tetrathyridia was able to
ameliorate or suppress fibrogenesis in the liver, protect
liver cells from oxidative damage and, possibly, stimulate
regeneration of the parenchyma. Interestingly, the
reduction in HYP content in the group treated with sily-
marin plus PZQ did not reach a significant level com-
pared with the PZQ treated group. Silymarin is thought
to be dose-dependent and studies vary considerably in
duration without agreement on the minimum duration
needed to see the effect [54,55]. Therefore, further stu-
dies are clearly needed to investigate the efficacy of
higher doses and a longer duration of treatment with
silymarin in this model of liver fibrosis.
In conclusion, silymarin has partially toxic effects on
worms and eggs. Furthermore, the anti-fibrotic and anti-
inflammatory effects of silymarin/PZQ alone were
observed in the acute and chronic fibrogenesis induced
by S. mansoni infection. This was evident in diminishing
hepatic content of HYP, serum levels and hepatic expres-
sion of TGF-b1 and MMP-2 and the number of mast
cells. These effects were more obvious in most para-
meters studied, when silymarin was used with the
removal of the causative agent by PZQ. Accordingly, our
results point to silymarin as a convenient and promising
therapeutic agent in the treatment of schistosomal liver
fibrosis. Further studies on mechanisms of action of sily-
marin and praziquantel during schistosomal liver fibrosis
or other chronic liver diseases may shed some light on
developing therapeutic methods in clinical practice.
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